In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

When is a Target Not a Target?

Executive Summary

Medarex is reevaluating its plans to bring 10 antibodies into the clinic each year, in part because targets identified by its array of young partners are taking a lot of work to validate. The company has gained appreciation for vaccines and for the potential of using antibodies as general immune stimulants rather than specifically targeted therapeutics.

You may also be interested in...



Wanted: Drug Hunters

The process of hunting for drugs is now markedly different than it was a few decades ago, partly because research organizations are much bigger and market pressures more intense. Technology has catalyzed the biggest shifts, decreasing the role of individuals and putting more emphasis on method than conceptualization. But the high-tech methods haven't been as productive as expected, and so research executives are increasingly considering which of the traditional ways might be worth recapturing.

Antibodies, Everyone?

A cluster of recent deals indicates just how hot antibodies are right now, and also hints at some old difficulties and new opportunities in the field.

American Injectables $10m Investment Bolsters Domestic Production

American Injectables plans to build up its US-based manufacturing after securing a commitment for $10m of ‘Series A’ financing from New Rhein Healthcare Investors, which it will use to scale up production and launch several generic parenteral products.

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT142313

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel